NASHVILLE, TN (June 17, 2019) - Aegis Sciences Corporation is pleased to announce that effective June 17, 2019 we will be...
Findings of a recently published two-part study demonstrate that InterACT Rx™ can significantly enhance diagnosis and treatment of DDIs, improving...
Studies show an alarming prevalence of concurrent ingestion of interacting substances by patients and that providing physicians with clear, objective...
Nashville, Tennessee (Nov. 5, 2018) - Aegis Sciences Corporation is pleased to announce definitive testing for kratom (mitragynine) via liquid chromatography-...
Employing a definitive test to detect substances whose interactions may cause adverse drug events can enhance a provider’s insights, drive clinical...
InterACT Rx™ identified at least one drug-drug interaction (DDI) between recently ingested substances in as many as 20% of patients. Nashville,...
Sign up for the Aegis Newsletter